Anaqua macht ausländische Patentanmeldungen zu einem strategischen Vorteil für IP-Profis
April 18, 2024 07:00 ET
|
Anaqua
BOSTON / MÜNCHEN, April 18, 2024 (GLOBE NEWSWIRE) -- Anaqua, der führende Anbieter von Innovations- und IP-Management-Technologien, kündigt die Weiterentwicklung seines Angebots für...
Edmonton Unlimited Welcomes New CEO, Tom Viinikka
April 17, 2024 10:30 ET
|
Edmonton Unlimited
Edmonton, Alberta, April 17, 2024 (GLOBE NEWSWIRE) -- Edmonton Unlimited is pleased to announce the appointment of Tom Viinikka as its new CEO, empowering the organization to scale and deliver on...
EZLynx Launches Industry-First Quote By Text Innovation
April 17, 2024 09:00 ET
|
EZLynx
Lewisville, TX., April 17, 2024 (GLOBE NEWSWIRE) -- EZLynx, an Applied company, today announced its latest personal lines rating innovation, Quote By Text, an insurance industry-first quoting...
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
April 17, 2024 01:15 ET
|
Novartis Pharma AG
Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis...
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
April 16, 2024 04:35 ET
|
Boehringer Ingelheim
Human Pharma sales up 10.3%* to EUR 20.8 bn, driven by JARDIANCE® and OFEV®Animal Health sales up 6.9 %* to EUR 4.7 bn, fueled by new product launchesR&D expenditures increase by 14.2% to EUR 5.8...
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
April 15, 2024 14:00 ET
|
Novartis Pharma AG
APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN1IgAN is a heterogeneous, progressive, rare...
Canadian innovation taking plant-protein nutrition to new heights
April 15, 2024 13:00 ET
|
Protein Industries Canada
Toronto, Ont., April 15, 2024 (GLOBE NEWSWIRE) -- Today, Protein Industries Canada held a tasting and networking event to celebrate the launch of its latest project announcement: A collaborative...
London Research & Pharmaceuticals presents the advancement of LRP-661, their oral cannabidiol sulphate drug candidate at the prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII conference in Miami
April 15, 2024 08:00 ET
|
London Research and Pharmaceuticals
London Research & Pharmaceuticals Corp. Presents the Advancement of their Oral Cannabidiol Sulphate Drug Candidate at Epilepsy Therapies Conference
InterDigital and Concordia University Announce Research Collaboration on AI-enabled Immersive Media Delivery over 5G Networks
April 15, 2024 04:00 ET
|
InterDigital, Inc.
WILMINGTON, Del., April 15, 2024 (GLOBE NEWSWIRE) -- InterDigital, Inc. (Nasdaq: IDCC), a mobile, video and AI technology research and development company, and Concordia University’s Intelligent...
Acceleware to Commence Next Phase of Mining Project: CTI-Powered Potash Ore Drying with Saskatchewan’s International Minerals Innovation Institute
April 11, 2024 08:21 ET
|
Acceleware Limited
CALGARY, Alberta, April 11, 2024 (GLOBE NEWSWIRE) -- Acceleware Ltd. (“Acceleware” or the “Company”) (TSX-V: AXE), a leading innovator of transformative technologies targeting the decarbonization of...